Paz-Ares L, Champiat S, Lai WV, Izumi H, et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T cell engager, in recurrent small-cell lung cancer: an open-label, phase 1 study. J Clin Oncol 2023 Jan 23:101200JCO2202823. doi: 10.1200/JCO.22.02823.
PMID: 36689692